The landscape of medical radiotherapeutics is rapidly evolving, showcasing a multitude of innovative treatments that target specific cancers and related symptoms with unprecedented precision. Utilising various radionuclides, these therapies represent a new frontier in the fight against cancer, offering hope for more effective and personalised treatment options.
Central to this advancement is the use of Actinium-225 (Ac-225), an alpha-emitting radionuclide, in a range of promising therapies. Alpha particles, with their high energy and short range, are effective in destroying cancer cells while minimising collateral damage to surrounding healthy tissues.
For instance, Ac-225-DOTA-SP targets Substance P receptors in glioblastoma, a notably aggressive brain tumour, delivering alpha radiation directly to the tumour site. This targeted approach is echoed in Ac-225-DOTA-YS5 and Ac-225-FPI-2265, both aimed at treating prostate cancer through different mechanisms. Ac-225-DOTA-YS5 targets CD46 using monoclonal antibody IgG1, whereas Ac-225-FPI-2265 focuses on the Prostate-Specific Membrane Antigen (PSMA) with PSMA-I&T.
The targeting of neuroendocrine tumours (NETs) has also seen significant developments with agents like Ac-225-DOTATOC and Ac-225-RYZ101, which focus on somatostatin receptors, delivering alpha radiation precisely to tumour cells. Further, Ac-225-DOTAZOL for bone pain palliation in patients with bone metastases exemplifies the versatility of radiotherapeutics, directly targeting bone tissues to provide pain relief.
Beyond alpha emitters, beta-emitting radionuclides like Yttrium-90 (Y-90) and Lutetium-177 (Lu-177) are also making strides in radiotherapeutics. Y-90 is employed in treating hepatocellular carcinoma and non-Hodgkin’s lymphoma, while Lu-177 is used in therapies for prostate cancer and neuroendocrine tumours.
Expanding the repertoire, treatments like At-211-81C6 mAb (Neuradiab) target brain cancer by using Astatine-211, another alpha emitter, conjugated with the monoclonal antibody 81C6. Similarly, At-211-MABG, targeting adrenergic tissues, is being developed for conditions like paragangliomas and pheochromocytoma.
Furthermore, Radium-223 (Ra-223) in Radium Dichloride therapy stands out for its application in bone pain palliation, particularly for metastatic prostate cancer. This therapy mimics calcium and selectively targets bone metastases, delivering alpha radiation.
The field also sees the development of therapies like Iodine-131 (I-131) in various forms, such as I-131-Apamistamab (Iomab-B™) for acute lymphoblastic leukaemia and Hodgkin’s lymphoma and I-131-Metuximab for hepatocarcinoma. Each of these I-131-based therapies leverages the beta radiation emitted by I-131 to target specific cancer cells.
In conclusion, the diversity of radiotherapeutics, from alpha and beta emitters to different targeting mechanisms, underscores the remarkable progress in this field. These therapies are advancing and redefining cancer treatment, offering more precise, effective, and patient-tailored options. As research and clinical trials continue, these groundbreaking developments in radiotherapeutics are poised to significantly impact the future of cancer therapy.
You are here:
home »
This article reviews key Phase III clinical trials for ALSYMPCA, NETTER-1, and VISION therapies, highlighting advancements in cancer treatment.
Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies Read Post »
Targeted Radionuclide Therapy for cancer delivers radioactive isotopes directly to tumour cells, maximising therapeutic effectiveness.
Biological Principles of Targeted Radionuclide Therapy for Cancer Read Post »
Iodine-131 IMAZA innovatively binds to adrenal cortex enzymes, revolutionizing the treatment and imaging of adrenocortical carcinoma effectively.
Iodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
Iodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
Iodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
Iodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
Targeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
Iodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
Holmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
Holmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
Holmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
The Role and Impact of Holmium-166 Microspheres in Brachytherapy Read Post »
The innovative 169Er-Erbium Citrate therapy precisely targets small joints, significantly easing arthritis with minimal side effects.
Erbium-169 Citrate: A Revolution in Small Joint Arthritis Treatment Read Post »
Copper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
Copper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy Read Post »
211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
Astatine-211 Sodium Astatide, evolving thyroid treatment, enters trials, promising enhanced precision and safety over traditional Iodine-131 NaI therapy.
Astatine-211 Sodium Astatide: The Next Generation in Thyroid Disease Treatment Read Post »
211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
The innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Post »
Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
Astatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation Read Post »
225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment Read Post »
225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
Actinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Post »
225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting Read Post »
225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
